Novanta (NOVT) AI Stock Analysis

Compare

213 Followers

Top Page

Novanta

(NASDAQ:NOVT)

Select Model

Neutral 62 (OpenAI - 5.2)

Rating:62Neutral

Price Target:

$121.00

▲(6.28% Upside)

Action:ReiteratedDate:02/24/26

The score is anchored by solid financial foundations (notably deleveraging) and constructive technical momentum, plus a bullish FY2026 outlook for margin and cash flow recovery from management. These positives are offset by the weak 2025 cash flow performance and a very expensive valuation (high P/E), which raises downside sensitivity if execution on the cash and margin rebound falls short.

Positive Factors

Balance sheet strength / net cash

A net cash position materially reduces financial risk and increases strategic flexibility. With low leverage management can fund R&D, complete regional manufacturing moves, and pursue M&A without stressing liquidity. This structural strength supports durable investment in growth initiatives.

New product momentum & design wins

Rapid new-product uptake and growing design wins indicate strong innovation and customer validation. Engineered, application-specific products drive higher lifetime revenue per OEM design-in and stickier relationships, supporting sustainable revenue and margin expansion over multiple equipment cycles.

Strong bookings, backlog and multi-year revenue growth

Elevated bookings and a backlog multiple provide multi-quarter revenue visibility and production cadence stability. Coupled with multi-year revenue growth to $981M in 2025, this structural demand supports steady organic growth and reduces short-term revenue volatility across medical and industrial end markets.

Negative Factors

Weakened operating cash flow in 2025

A sharp decline in operating and free cash flow materially reduces margin for error on investments, M&A, and working-capital variability. Even with guidance for a rebound, the 2025 cash contraction shows conversion sensitivity to inventory and operational timing, raising medium-term funding and execution risk.

Profitability / margin compression

A large step-down in operating profitability undermines cash generation and return on capital. Sustained margin pressure could limit ability to reinvest or pursue acquisitions profitably. Recovery hinges on successful cost actions and operational fixes; failure would weaken long-term earnings power.

Elevated working capital from regional transfers

Higher inventory and dual-running costs tie up cash and depress near-term conversion metrics. If regional transfer complexity or customer prioritization persists, working-capital drag could remain structural, limiting flexibility and delaying the anticipated cash flow recovery even if revenue improves.

Novanta (NOVT) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$4.06B

Dividend YieldN/A

Average Volume (3M)429.21K

Price to Earnings (P/E)80.9

Beta (1Y)1.69

Revenue Growth4.07%

EPS Growth-12.34%

CountryUS

Employees3,000

SectorTechnology

Sector Strength88

IndustryHardware, Equipment & Parts

Share Statistics

EPS (TTM)0.91

Shares Outstanding35,683,770

10 Day Avg. Volume450,188

30 Day Avg. Volume429,207

Financial Highlights & Ratios

PEG Ratio-4.64

Price to Book (P/B)3.31

Price to Sales (P/S)4.44

P/FCF Ratio89.90

Enterprise Value/Market Cap0.99

Enterprise Value/Revenue4.10

Enterprise Value/Gross Profit9.24

Enterprise Value/Ebitda24.12

Forecast

1Y Price Target

$150.00

Price Target Upside31.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)3.61

Revenue Forecast (FY)$1.04B

Novanta Business Overview & Revenue Model

Company DescriptionNovanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The company's Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. It's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. In addition, its Precision Motion segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts.

How the Company Makes MoneyNovanta makes money primarily by selling engineered components, modules, and subsystems to OEM customers that incorporate Novanta technology into their own branded equipment. Revenue is generated from (1) product sales of photonics and laser-related components and subsystems (e.g., laser sources/beam delivery and related enabling technologies) used in medical and industrial systems, (2) sales of vision, sensor, and precision motion/automation components (e.g., encoders, motion control, and vision-related hardware) used in robotics and factory automation, and (3) sales of integrated OEM subassemblies and customized solutions built to customer specifications. The company’s model is largely B2B and design-in driven: once a component is qualified and designed into an OEM platform, Novanta can benefit from repeat production orders over the life of the customer’s equipment program. Earnings are supported by a mix of standard catalog products and higher-value custom or application-specific engineered products, and by serving regulated medical markets where qualification cycles can increase customer switching costs. Information on specific customer names, contract structures (e.g., long-term supply agreements), or explicit revenue splits by product line is null.

Novanta Key Performance Indicators (KPIs)

Any

Revenue by Geography

Chart InsightsNovanta's top-line is being driven by the U.S., which accounts for the bulk of revenue and has shown consistent acceleration; non-U.S. markets—notably China and Rest of Europe—have rebounded recently, helping offset weakness in Germany and small 'Other' markets. Management's booking growth and surging design wins validate the geographic recovery and support mid-single-digit organic guidance, but call details flag an underlying organic revenue contraction and Precision Medicine softness that could blunt near-term upside if bookings don't convert.

Data provided by:

The Fly

Novanta Earnings Call Summary

Earnings Call Date:Feb 23, 2026

(Q4-2025)

% Change Since: |

Next Earnings Date:May 12, 2026

Earnings Call Sentiment Positive

The call featured strong operational momentum: record revenue, broad-based double-digit bookings, significant new product traction, improved backlog, adjusted EBITDA and EPS growth, a net cash position, and robust 2026 guidance (revenue, margins, EBITDA, and cash flow). The main negatives were temporary and operational: Q4 margin compression, higher working capital and inventory from prioritized customer deliveries and regional manufacturing transfers, and a sharp Q4 cash flow decline. Management provided clear remediation actions (cost adjustments in January, completion of transfers by end of Q2) and reiterated confidence in margin expansion and cash rebound in 2026. On balance, the positive indicators and expected recovery outweigh the transitory headwinds.

Q4-2025 Updates

Positive Updates

Record Quarterly and Full-Year Revenue

Q4 record revenue with 9% reported growth, 2% organic growth, and 4% sequential growth; full-year 2025 revenue of $981 million (company's largest year ever).

Strong Bookings and Backlog

Bookings surged 25% year-over-year and 12% sequentially in Q4 with company book-to-bill of 1.11; full-year bookings up 14% with a full-year book-to-bill of 1.01; multiple business units reported book-to-bill >1 and backlogs ~1.5–2x quarterly revenue.

Robust New Product Momentum

New product sales in Q4 grew >80% year-over-year (vitality index 24%); full-year new product sales up >60% (vitality index 22%); company-wide design wins up >20% year-over-year.

Profitability Expansion (Non-GAAP)

Q4 adjusted EBITDA grew 17% year-over-year to $61 million with a 23.5% adjusted EBITDA margin; Q4 adjusted diluted EPS up 20% year-over-year ($0.91). Full-year adjusted EPS $3.29 (+7% YoY).

Net Cash Position and Deleveraging

Ended Q4 with $381 million cash and gross debt $260 million, net debt negative $121 million (net leverage ratio -0.5x); revolver reduced by >$300 million using November fundraise proceeds.

Acquisition Firepower

Raised >$600 million in November and report ~ $1.5 billion total acquisition capacity; management expects to deploy meaningful capital in 2026 to accelerate growth.

Positive 2026 Outlook and Guidance

FY2026 revenue guidance $1,030M–$1,050M (4%–6% organic growth); adjusted gross margin target ~47% (+100 bps YoY); adjusted EBITDA $245M–$250M (~24% margin); EPS $3.50–$3.65 (up to 11% YoY); operating cash flow guide $145M–$185M (more than double 2025).

Broad-Based End-Market Strength

Medical Solutions: Q4 revenue +16% YoY, advanced surgery business ~15% growth and strong consumables traction; Robotics & Automation: Q4 revenue +6% YoY with traction in GPU board drilling and warehouse/humanoid wins; Precision Manufacturing bookings up 4 consecutive quarters.

Negative Updates

Gross Margin Compression in Q4

Q4 non-GAAP adjusted gross margin declined to 45.5% from 47% in prior year (down 150 bps YoY and down 100 bps sequentially); management attributed >100 bps impact to deliberate decision to prioritize customer deliveries over timing of regional manufacturing transfers.

Significant Working Capital and Inventory Build

Regional manufacturing transfers caused elevated dual-running costs and inventory, producing ~400 bps increase to net working capital as a percent of sales and pressuring near-term cash flow.

Weakened Operating Cash Flow

Q4 operating cash flow fell to $9 million from $62 million year-ago; full-year operating cash flow was $64 million, materially below prior year and guidance targets for cash conversion (expected to rebound in 2026).

Temporary EPS Headwinds from Fundraise and Equity Grant

November equity fundraise increased diluted share count by ~2.7 million and will exert a ~$0.22–$0.24 EPS headwind in 2026; a one-time all-employee equity grant creates an additional ~$0.14 EPS impact in 2026 first half.

Segment Weakness — Precision Manufacturing

Precision manufacturing revenue declined 3% year-over-year in Q4 despite sequential growth of 8%; this segment remains in recovery though bookings are accelerating.

Margins & Cash Below Prior Guidance

Management acknowledged margins and cash flow came in below expectations set on the prior call due to the deliberate decision on transfers, creating short-term performance drag despite corrective actions taken in January.

Company Guidance

Management guided FY‑2026 GAAP revenue of $1,030–$1,050M (4–6% organic growth) with Q1 revenue $250–$255M (organic +1% to +3%, reported +7% to +9%) and sequential organic acceleration to ~+5%–+7% in Q2 and similar in the back half; adjusted gross margin is expected to be ~47% for the year (~+100 bps vs 2025) with Q1 at ~46.5%. They forecast R&D+SG&A of $294–$298M (~28% of sales) and Q1 opex of ~$76–$77M (~30% of sales), depreciation ~$17M FY, stock compensation ~$38M FY (Q1 ~$12M, Q2 ~$11M, then ~ $8M/quarter). Adjusted EBITDA is guided to $245–$250M (~24% margin, low double‑digit growth) with Q1 adjusted EBITDA $56–$58M (up 12–17% YoY); interest expense ~ $8M FY (~$2M Q1); non‑GAAP tax ~21% FY (19–20% Q1); diluted shares ~41M; diluted EPS $3.50–$3.65 FY (up to 11% YoY, including a $0.22–$0.24 headwind from the equity raise and a one‑time $0.14 equity‑grant impact), and Q1 adj. EPS $0.75–$0.80 (up ~8% YoY). Finally, operating cash flow is expected to rebound to $145–$185M for FY‑2026 (Q1 cash conversion >100% of GAAP net income), with regional manufacturing transfers to be completed by end of Q2.

Novanta Financial Statement Overview

Summary

Strong multi-year revenue growth and a materially improved leverage profile (net cash position supported by lower debt-to-equity), but 2025 showed meaningful pressure in profitability (EBITDA margin compression) and a sharp deterioration in operating/free cash flow, which is a key near-term risk.

Income Statement

Positive

Revenue has grown steadily over the last several years (from $591M in 2020 to $981M in 2025), with a very strong 2025 growth rate shown in the data. Profitability, however, has softened recently: net margin fell to ~5.5% in 2025 from ~6.8% in 2024, and EBITDA margin compressed to ~9.6% in 2025 from ~18.9% in 2024. Gross margin remains relatively stable around the mid-40% range, but the step-down in operating-level profitability is a key concern.

Balance Sheet

Positive

Leverage has improved meaningfully, with debt-to-equity declining from ~0.95 (2021) to ~0.63 (2024) and down to ~0.23 in 2025, indicating a stronger capital structure and lower financial risk. Equity also expanded sharply in 2025, supporting balance sheet flexibility. The main watch item is the year-to-year volatility in the capital base and debt levels (which can reflect acquisition activity, financing moves, or accounting impacts), but overall balance sheet strength looks improved.

Cash Flow

Neutral

Cash generation weakened materially in 2025: operating cash flow dropped to ~$64M from ~$159M in 2024, and free cash flow fell to ~$48M from ~$141M (down ~53% year over year). Free cash flow still covered net income reasonably (about 76% in 2025), but the sharp decline in absolute cash flow and the much lower cash conversion versus 2024 are notable risks and reduce financial flexibility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	980.60M	949.25M	881.66M	860.90M	706.79M
Gross Profit	435.28M	421.55M	399.90M	378.47M	300.33M
EBITDA	153.05M	179.86M	169.92M	160.62M	125.47M
Net Income	53.83M	64.09M	72.88M	74.05M	50.33M
Balance Sheet
Total Assets	1.81B	1.39B	1.23B	1.24B	1.23B
Cash, Cash Equivalents and Short-Term Investments	380.87M	113.99M	105.05M	100.11M	117.39M
Total Debt	341.61M	471.00M	404.56M	489.38M	493.40M
Total Liabilities	492.82M	642.81M	552.60M	663.63M	706.59M
Stockholders Equity	1.31B	745.70M	673.46M	577.59M	521.29M
Cash Flow
Free Cash Flow	48.43M	141.35M	100.11M	71.14M	72.45M
Operating Cash Flow	64.06M	158.51M	120.08M	90.78M	94.63M
Investing Cash Flow	-74.32M	-208.19M	-19.89M	-42.54M	-306.70M
Financing Cash Flow	276.33M	56.94M	-97.85M	-60.15M	204.75M

Novanta Technical Analysis

Technical Analysis Sentiment

Negative

Last Price113.85

Price Trends

50DMA

134.28

Negative

100DMA

125.40

Negative

200DMA

121.79

Negative

Market Momentum

MACD

-5.51

Positive

RSI

32.38

Neutral

STOCH

21.55

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOVT, the sentiment is Negative. The current price of 113.85 is below the 20-day moving average (MA) of 128.76, below the 50-day MA of 134.28, and below the 200-day MA of 121.79, indicating a bearish trend. The MACD of -5.51 indicates Positive momentum. The RSI at 32.38 is Neutral, neither overbought nor oversold. The STOCH value of 21.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NOVT.

Novanta Risk Analysis

Novanta disclosed 38 risk factors in its most recent earnings report. Novanta reported the most risks in the "Legal & Regulatory" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Novanta Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ESE	80 Outperform	$6.76B	44.07	21.34%	0.16%	13.13%	24.02%
VICR	77 Outperform	$7.47B	41.35	18.74%	―	11.55%	1745.46%
PLXS	74 Outperform	$5.22B	24.74	12.39%	―	1.82%	56.52%
OSIS	68 Neutral	$4.52B	27.58	16.91%	―	9.37%	15.70%
ST	68 Neutral	$4.84B	155.81	1.11%	1.43%	-8.07%	63.50%
NOVT	62 Neutral	$4.06B	80.88	5.84%	―	4.07%	-12.34%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

* Technology Sector Average

Performance Comparison

NOVT

Novanta

113.85

-23.66

-17.21%

ESE

Esco Technologies

260.95

94.82

57.07%

OSIS

OSI Systems

274.45

71.13

34.98%

PLXS

Plexus

195.00

62.20

46.84%

Sensata

33.18

5.81

21.23%

VICR

Vicor

164.54

109.17

197.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 24, 2026